Neogen announces board retirement of William Boehm, appointment of Avi Pelossof effective Oct 23/24

NEOGEN CORP

William T. Boehm to retire from Neogen's Board effective Oct 23, 2025; served since 2011, chairs Audit Committee, member of Compensation & Talent Management Committee.
Avi Pelossof appointed to Board effective Oct 24, 2025 as Class II director; over 25 yrs in diagnostics market, most recently CEO of Immucor.
Pelossof previously Global President, Infectious Disease at Alere Inc., building a $750M portfolio and launching FDA CLIA-waived point-of-care test (now Abbott's ID NOW).
Pelossof will participate in Neogen's non-employee director compensation program as described in 2024 proxy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.